El interés en corto de Jowell Global da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Jowell Global. Los datos de interés en corto se actualizan cada dos semanas.

Jowell Global (NASDAQ:JWEL) Bolsa, Informe de interés en corto

Jowell Global

Jowell Global Ltd is a cosmetics, health and nutritional supplements, and household products e-commerce platform. It operates under Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing sales channels. The company's major merchandise categories are Cosmetic products, Health and nutritional supplements, and Household Products.

Jowell Global Ltd

<p>CF Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFBK#NASDAQ">CFBK</a>) reported quarterly earnings of $0.68 per share. This is a 44.68 percent increase over earnings of $0.47 per share from the same period last year.  The company reported $14.12 million in sales this quarter. This is a 15.80 percent increase over sales of $12.19 million the same period last year.</p>


Earnings

News

CFBK

CF Bankshares Q1 EPS $0.68 Up From $0.47 YoY, Sales $14.12M Up From $12.19M YoY

<p><strong>TruBridge</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBRG#NASDAQ">TBRG</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-05-07. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that TruBridge will report an <strong>earnings per share</strong> (EPS) of $0.29. </p>
<p>The market awaits TruBridge's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.34, leading to a 7.49% increase in the share price on the subsequent day.</p>
<p>Here's a look at TruBridge's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.39</td>
<td>0.27</td>
<td>0.17</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.05</td>
<td>-0.21</td>
<td>0.16</td>
<td>0.19</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>7.000000000000001%</td>
<td>-0.0%</td>
<td>24.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746547423_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of TruBridge were trading at $26.29 as of May 05. Over the last 52-week period, shares are up 211.12%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Opinions on TruBridge</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on TruBridge.</p>
<p>Analysts have given TruBridge a total of 3 ratings, with the consensus rating being Neutral. The average one-year price target is $28.33, indicating a potential 7.76% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Claritev, Definitive Healthcare and Health Catalyst, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Claritev, with an average 1-year price target of $19.0, suggesting a potential 27.73% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Definitive Healthcare, with an average 1-year price target of $3.0, suggesting a potential 88.59% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Health Catalyst, with an average 1-year price target of $5.81, suggesting a potential 77.9% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Claritev, Definitive Healthcare and Health Catalyst, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>TruBridge</td>
<td>Neutral</td>
<td>10.26%</td>
<td>$49.78M</td>
<td>-1.72%</td>
</tr>
<tr>
<td>Claritev</td>
<td>Neutral</td>
<td>-4.91%</td>
<td>$175.01M</td>
<td>-94.63%</td>
</tr>
<tr>
<td>Definitive Healthcare</td>
<td>Neutral</td>
<td>-5.53%</td>
<td>$47.60M</td>
<td>-12.43%</td>
</tr>
<tr>
<td>Health Catalyst</td>
<td>Neutral</td>
<td>6.02%</td>
<td>$34.69M</td>
<td>-5.74%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>TruBridge ranks at the bottom for Revenue Growth and Gross Profit, while it ranks in the middle for Return on Equity.</p>
<h3>Unveiling the Story Behind TruBridge</h3>
<p>TruBridge Inc is a provider of healthcare solutions and services for community hospitals, clinics, and other healthcare systems. It provides services such as Electronic health records &amp; information systems, revenue cycle management, population health, and data management, etc. The segments of the company are Revenue Cycle Management (RCM), (ii) Electronic Health Records (EHR), and (iii) Patient Engagement The company derives maximum revenue from the RCM segment.</p>
<h3>TruBridge: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> TruBridge displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>10.26%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> TruBridge's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-3.23%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> TruBridge's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-1.72%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> TruBridge's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.74%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.04</strong>.</p>
<p><a href="https://www.benzinga.com/quote/TBRG/earnings"><strong>To track all earnings releases for TruBridge visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


TBRG

Insights Ahead: TruBridge's Quarterly Earnings

<p>Piper Sandler  analyst David Amsellem   reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Overweight and lowers the price target from $160 to $154.</p>


Price Target

Reiteration

Analyst Ratings

NBIX

Piper Sandler Reiterates Overweight on Neurocrine Biosciences, Lowers Price Target to $154

<p><strong>Miller Industries</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLR#NYSE">MLR</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-05-07. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Miller Industries will report an <strong>earnings per share</strong> (EPS) of $0.60. </p>
<p>Miller Industries bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS missed by $0.18 in the last quarter, leading to a 15.31% drop in the share price on the following day.</p>
<p>Here's a look at Miller Industries's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.09</td>
<td>1.33</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.91</td>
<td>1.33</td>
<td>1.78</td>
<td>1.47</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-15.0%</td>
<td>-10.0%</td>
<td>-3.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Market Performance of Miller Industries's Stock</h3>
<p>Shares of Miller Industries were trading at $42.45 as of May 05. Over the last 52-week period, shares are down 23.47%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MLR/earnings"><strong>To track all earnings releases for Miller Industries visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Outlook For Miller Industries

<p><strong>Vir Biotechnology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-05-07. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Vir Biotechnology will report an <strong>earnings per share</strong> (EPS) of $-0.84. </p>
<p>Vir Biotechnology bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company beat EPS by $0.11, which was followed by a 11.85% drop in the share price the next day.</p>
<p>Here's a look at Vir Biotechnology's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.87</td>
<td>-1.05</td>
<td>-0.89</td>
<td>-1.05</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.76</td>
<td>-1.56</td>
<td>-1.02</td>
<td>-0.48</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-12.0%</td>
<td>24.0%</td>
<td>-5.0%</td>
<td>13.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746547399_0.png" alt="eps graph" /></p>
<h3>Performance of Vir Biotechnology Shares</h3>
<p>Shares of Vir Biotechnology were trading at $6.15 as of May 05. Over the last 52-week period, shares are down 38.99%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Analyst Observations about Vir Biotechnology</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Vir Biotechnology.</p>
<p>With 4 analyst ratings, Vir Biotechnology has a consensus rating of Buy. The average one-year price target is $45.25, indicating a potential 635.77% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of CareDx, Ardelyx and MiMedx Group, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for CareDx, with an average 1-year price target of $31.2, suggesting a potential 407.32% upside.</li>
<li>Analysts currently favor an Buy trajectory for Ardelyx, with an average 1-year price target of $10.9, suggesting a potential 77.24% upside.</li>
<li>Analysts currently favor an Outperform trajectory for MiMedx Group, with an average 1-year price target of $13.0, suggesting a potential 111.38% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary presents essential metrics for CareDx, Ardelyx and MiMedx Group, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vir Biotechnology</td>
<td>Buy</td>
<td>17.45%</td>
<td>$10.59M</td>
<td>-8.75%</td>
</tr>
<tr>
<td>CareDx</td>
<td>Neutral</td>
<td>17.54%</td>
<td>$56.27M</td>
<td>-2.73%</td>
</tr>
<tr>
<td>Ardelyx</td>
<td>Buy</td>
<td>61.04%</td>
<td>$61.81M</td>
<td>-25.80%</td>
</tr>
<tr>
<td>MiMedx Group</td>
<td>Outperform</td>
<td>4.13%</td>
<td>$71.65M</td>
<td>3.55%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Vir Biotechnology ranks at the bottom for Revenue Growth and Gross Profit, with the lowest percentage growth and profit among its peers. However, it has the highest Return on Equity, indicating strong performance relative to its equity. The Consensus rating for Vir Biotechnology is mixed compared to its peers.</p>
<h3>Delving into Vir Biotechnology's Background</h3>
<p>Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.</p>
<h3>Unraveling the Financial Story of Vir Biotechnology</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Vir Biotechnology showcased positive performance, achieving a revenue growth rate of <strong>17.45%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Vir Biotechnology's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-927.37%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-8.75%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-7.22%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.09</strong>, Vir Biotechnology adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/VIR/earnings"><strong>To track all earnings releases for Vir Biotechnology visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Outlook For Vir Biotechnology

<p>OTC Markets Gr (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OTCM#OTC">OTCM</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that OTC Markets Gr will report an <strong>earnings per share</strong> (EPS) of $0.53.</p>
<p>The announcement from OTC Markets Gr is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.21, which was followed by a 3.67% drop in the share price the next day.</p>
<p>Here's a look at OTC Markets Gr's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.70</td>
<td>0.60</td>
<td>0.66</td>
<td>0.57</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.91</td>
<td>0.89</td>
<td>0.85</td>
<td>0.76</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>-4.0%</td>
<td>-1.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746547386_0.png" alt="eps graph" /></p>
<h3>Market Performance of OTC Markets Gr's Stock</h3>
<p>Shares of OTC Markets Gr were trading at $47.7 as of May 05. Over the last 52-week period, shares are down 6.79%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/OTCM/earnings"><strong>To track all earnings releases for OTC Markets Gr visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


OTCM

What's Next: OTC Markets Gr's Earnings Preview

<p>Scotiabank  analyst George Farmer   maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Sector Perform and raises the price target from $16 to $17.</p>


SNDX

Scotiabank Maintains Sector Perform on Syndax Pharmaceuticals, Raises Price Target to $17

<p>Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Avadel Pharmaceuticals will report an <strong>earnings per share</strong> (EPS) of $-0.06.</p>
<p>Avadel Pharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company missed EPS by $0.01, which was followed by a 1.19% increase in the share price the next day.</p>
<p>Here's a look at Avadel Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.04</td>
<td>-0.05</td>
<td>-0.16</td>
<td>-0.21</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.05</td>
<td>-0.03</td>
<td>-0.14</td>
<td>-0.30</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-9.0%</td>
<td>-1.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746547376_0.png" alt="eps graph" /></p>
<h3>Market Performance of Avadel Pharmaceuticals's Stock</h3>
<p>Shares of Avadel Pharmaceuticals were trading at $9.04 as of May 05. Over the last 52-week period, shares are down 44.06%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/AVDL/earnings"><strong>To track all earnings releases for Avadel Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Earnings Outlook For Avadel Pharmaceuticals

<p>EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) will release its quarterly earnings report on Wednesday, 2025-05-07. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate EyePoint Pharmaceuticals to report an <strong>earnings per share</strong> (EPS) of $-0.55.</p>
<p>Anticipation surrounds EyePoint Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS missed by $0.16 in the last quarter, leading to a 3.65% increase in the share price on the following day.</p>
<p>Here's a look at EyePoint Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.48</td>
<td>-0.55</td>
<td>-0.52</td>
<td>-0.42</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.64</td>
<td>-0.54</td>
<td>-0.58</td>
<td>-0.55</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>0.0%</td>
<td>6.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746547366_0.png" alt="eps graph" /></p>
<h3>EyePoint Pharmaceuticals Share Price Analysis</h3>
<p>Shares of EyePoint Pharmaceuticals were trading at $6.86 as of May 05. Over the last 52-week period, shares are down 43.25%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Analysts' Perspectives on EyePoint Pharmaceuticals</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on EyePoint Pharmaceuticals.</p>
<p>EyePoint Pharmaceuticals has received a total of 3 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $29.33, the consensus suggests a potential 327.55% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Eton Pharmaceuticals, Tilray Brands and Zevra Therapeutics, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Eton Pharmaceuticals, with an average 1-year price target of $27.67, suggesting a potential 303.35% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Tilray Brands, with an average 1-year price target of $1.0, suggesting a potential 85.42% downside.</li>
<li>Analysts currently favor an Buy trajectory for Zevra Therapeutics, with an average 1-year price target of $22.0, suggesting a potential 220.7% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for Eton Pharmaceuticals, Tilray Brands and Zevra Therapeutics are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>EyePoint Pharmaceuticals</td>
<td>Buy</td>
<td>-17.39%</td>
<td>$10.77M</td>
<td>-14.91%</td>
</tr>
<tr>
<td>Eton Pharmaceuticals</td>
<td>Buy</td>
<td>59.26%</td>
<td>$6.48M</td>
<td>-2.96%</td>
</tr>
<tr>
<td>Tilray Brands</td>
<td>Neutral</td>
<td>-1.36%</td>
<td>$52.01M</td>
<td>-25.45%</td>
</tr>
<tr>
<td>Zevra Therapeutics</td>
<td>Buy</td>
<td>-6.79%</td>
<td>$10.68M</td>
<td>-65.31%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>EyePoint Pharmaceuticals ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, it is at the bottom.</p>
<h3>About EyePoint Pharmaceuticals</h3>
<p>EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.</p>
<h3>Key Indicators: EyePoint Pharmaceuticals's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> EyePoint Pharmaceuticals's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-17.39%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> EyePoint Pharmaceuticals's net margin excels beyond industry benchmarks, reaching <strong>-357.26%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> EyePoint Pharmaceuticals's ROE excels beyond industry benchmarks, reaching <strong>-14.91%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> EyePoint Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-11.51%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> EyePoint Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of <b>0.06</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/EYPT/earnings"><strong>To track all earnings releases for EyePoint Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


EYPT

A Peek at EyePoint Pharmaceuticals's Future Earnings

<p>Tutor Perini (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) will release its quarterly earnings report on Wednesday, 2025-05-07. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Tutor Perini to report an <strong>earnings per share</strong> (EPS) of $0.09.</p>
<p>The market awaits Tutor Perini's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS missed by $1.61 in the last quarter, leading to a 34.39% increase in the share price on the following day.</p>
<p>Here's a look at Tutor Perini's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.10</td>
<td>-1.89</td>
<td>0.19</td>
<td>-0.17</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.51</td>
<td>-1.92</td>
<td>0.19</td>
<td>0.30</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>34.0%</td>
<td>10.0%</td>
<td>-27.0%</td>
<td>28.000000000000004%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746547351_0.png" alt="eps graph" /></p>
<h3>Market Performance of Tutor Perini's Stock</h3>
<p>Shares of Tutor Perini were trading at $22.76 as of May 05. Over the last 52-week period, shares are up 27.63%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/TPC/earnings"><strong>To track all earnings releases for Tutor Perini visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


An Overview of Tutor Perini's Earnings

<p>Piper Sandler  analyst Adam Maeder   downgrades Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) from Overweight to Neutral and lowers the price target from $25 to $14.</p>


Downgrades

TCMD

Piper Sandler Downgrades Tactile Systems Tech to Neutral, Lowers Price Target to $14

<p>Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Groupon to report an <strong>earnings per share</strong> (EPS) of $-0.11.</p>
<p>Groupon bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS missed by $1.41 in the last quarter, leading to a 43.09% increase in the share price on the following day.</p>
<p>Here's a look at Groupon's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.21</td>
<td>-0.16</td>
<td>0.03</td>
<td>0.05</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.20</td>
<td>0.33</td>
<td>-0.02</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>43.0%</td>
<td>-27.0%</td>
<td>-15.0%</td>
<td>24.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746547343_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Groupon were trading at $16.78 as of May 05. Over the last 52-week period, shares are up 56.76%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Opinions on Groupon</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Groupon.</p>
<p>Analysts have given Groupon a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $17.33, indicating a potential 3.28% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of  and Kohl's, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Kohl's, with an average 1-year price target of $8.46, suggesting a potential 49.58% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for  and Kohl's, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Groupon</td>
<td>Buy</td>
<td>-5.33%</td>
<td>$118.19M</td>
<td>-125.35%</td>
</tr>
<tr>
<td>Kohl's</td>
<td>Neutral</td>
<td>-9.39%</td>
<td>$1.92B</td>
<td>1.26%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Groupon ranks lower in revenue growth compared to its peers. It also has a negative gross profit margin, indicating lower profitability. Additionally, Groupon has a significantly negative return on equity, suggesting lower returns for shareholders.</p>
<h3>Get to Know Groupon Better</h3>
<p>Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.</p>
<h3>Key Indicators: Groupon's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Groupon's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-5.33%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Groupon's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-38.85%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Groupon's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-125.35%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-8.73%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>6.2</strong>, caution is advised due to increased financial risk.</p>
<p><a href="https://www.benzinga.com/quote/GRPN/earnings"><strong>To track all earnings releases for Groupon visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


GRPN

Examining the Future: Groupon's Earnings Outlook

<p>Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Compass Minerals Intl to report an <strong>earnings per share</strong> (EPS) of $0.00.</p>
<p>Anticipation surrounds Compass Minerals Intl's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS missed by $0.50 in the last quarter, leading to a 5.78% drop in the share price on the following day.</p>
<p>Here's a look at Compass Minerals Intl's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.05</td>
<td>-0.45</td>
<td>-0.74</td>
<td>0.27</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.55</td>
<td>-0.77</td>
<td>-1.01</td>
<td>1.49</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>1.0%</td>
<td>-3.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746547311_0.png" alt="eps graph" /></p>
<h3>Market Performance of Compass Minerals Intl's Stock</h3>
<p>Shares of Compass Minerals Intl were trading at $13.6 as of May 05. Over the last 52-week period, shares are up 2.75%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CMP/earnings"><strong>To track all earnings releases for Compass Minerals Intl visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


What's Next: Compass Minerals Intl's Earnings Preview

<p>Citigroup  analyst James Hardiman   maintains Mattel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) with a Buy and raises the price target from $19 to $22.</p>


Citigroup Maintains Buy on Mattel, Raises Price Target to $22

<p>ProFrac Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACDC#NASDAQ">ACDC</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that ProFrac Holding will report an <strong>earnings per share</strong> (EPS) of $-0.32.</p>
<p>The market awaits ProFrac Holding's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS missed by $0.37, leading to a 7.14% increase in the share price on the subsequent day.</p>
<p>Here's a look at ProFrac Holding's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.30</td>
<td>-0.13</td>
<td>0.14</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.67</td>
<td>-0.29</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>7.000000000000001%</td>
<td>11.0%</td>
<td>-5.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746547299_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of ProFrac Holding were trading at $4.65 as of May 05. Over the last 52-week period, shares are down 35.12%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analysts' Perspectives on ProFrac Holding</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding ProFrac Holding.</p>
<p>Analysts have provided ProFrac Holding with 2 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $6.5, suggesting a potential 39.78% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Aris Water Solutions, NPK International and Solaris Energy, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Aris Water Solutions, with an average 1-year price target of $29.0, suggesting a potential 523.66% upside.</li>
<li>Analysts currently favor an Buy trajectory for NPK International, with an average 1-year price target of $12.0, suggesting a potential 158.06% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Solaris Energy, with an average 1-year price target of $48.6, suggesting a potential 945.16% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Aris Water Solutions, NPK International and Solaris Energy, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>ProFrac Holding</td>
<td>Neutral</td>
<td>-7.03%</td>
<td>$3.80M</td>
<td>-9.96%</td>
</tr>
<tr>
<td>Aris Water Solutions</td>
<td>Neutral</td>
<td>13.91%</td>
<td>$46.55M</td>
<td>1.10%</td>
</tr>
<tr>
<td>NPK International</td>
<td>Buy</td>
<td>32.29%</td>
<td>$25.25M</td>
<td>3.06%</td>
</tr>
<tr>
<td>Solaris Energy</td>
<td>Outperform</td>
<td>31.19%</td>
<td>$27.59M</td>
<td>1.41%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>ProFrac Holding ranks at the bottom for Revenue Growth among its peers. It also has the lowest Gross Profit margin. Additionally, it has the lowest Return on Equity. Overall, ProFrac Holding lags behind its peers in key financial metrics.</p>
<h3>All You Need to Know About ProFrac Holding</h3>
<p>ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. Its operations are focused in West Texas, East Texas/Louisiana, South Texas, Oklahoma, Uinta, and Appalachian. The company operates in three segments: Stimulation Services, Proppant Production, and Manufacturing. Stimulation services, which generate the majority of the revenue for the company operate a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services.</p>
<h3>A Deep Dive into ProFrac Holding's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Challenges:</strong> ProFrac Holding's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-7.03%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> ProFrac Holding's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-23.09%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> ProFrac Holding's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-9.96%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> ProFrac Holding's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-3.43%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.26</strong>, ProFrac Holding adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/ACDC/earnings"><strong>To track all earnings releases for ProFrac Holding visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ACDC

ProFrac Holding's Earnings: A Preview

<p>Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Apellis Pharmaceuticals will report an <strong>earnings per share</strong> (EPS) of $-0.34.</p>
<p>The announcement from Apellis Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.11, which was followed by a 0.0% drop in the share price the next day.</p>
<p>Here's a look at Apellis Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.40</td>
<td>-0.30</td>
<td>-0.32</td>
<td>-0.52</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.29</td>
<td>-0.46</td>
<td>-0.28</td>
<td>-0.54</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>3.0%</td>
<td>2.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746547279_0.png" alt="eps graph" /></p>
<h3>Performance of Apellis Pharmaceuticals Shares</h3>
<p>Shares of Apellis Pharmaceuticals were trading at $19.98 as of May 05. Over the last 52-week period, shares are down 53.25%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/APLS/earnings"><strong>To track all earnings releases for Apellis Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


APLS

Apellis Pharmaceuticals's Earnings Outlook

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Micron Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MU, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 23 uncommon options trades for Micron Technology.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 43% bullish and 39%, bearish.</p>
<p>Out of all of the special options we uncovered, 10 are puts, for a total amount of $1,508,116, and 13 are calls, for a total amount of $2,325,001.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $50.0 to $100.0 for Micron Technology over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Micron Technology stands at 5507.71, with a total volume reaching 10,991.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Micron Technology, situated within the strike price corridor from $50.0 to $100.0, throughout the last 30 days.</p>
<h3>Micron Technology Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746547253_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$4.0</td>
<td>$3.95</td>
<td>$3.95</td>
<td>$100.00</td>
<td>$1.5M</td>
<td>8.0K</td>
<td>4.0K</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$13.9</td>
<td>$13.75</td>
<td>$13.8</td>
<td>$80.00</td>
<td>$345.0K</td>
<td>3.1K</td>
<td>750</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$13.95</td>
<td>$13.75</td>
<td>$13.8</td>
<td>$80.00</td>
<td>$345.0K</td>
<td>3.1K</td>
<td>500</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$13.95</td>
<td>$13.75</td>
<td>$13.8</td>
<td>$80.00</td>
<td>$345.0K</td>
<td>3.1K</td>
<td>250</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$8.15</td>
<td>$8.0</td>
<td>$8.05</td>
<td>$80.00</td>
<td>$201.2K</td>
<td>3.4K</td>
<td>278</td>
</tr>
</tbody>
</table>
</p>
<h3>About Micron Technology</h3>
<p>Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.</p>
<p>After a thorough review of the options trading surrounding Micron Technology, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Micron Technology's Current Market Status</h3>
<ul>
<li>With a trading volume of 4,670,845, the price of MU is down by -0.82%, reaching $79.76.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 50 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Micron Technology</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $99.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Micron Technology, targeting a price of $92.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Micron Technology, targeting a price of $110.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Micron Technology with a target price of $95. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Micron Technology with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

A Closer Look at Micron Technology's Options Market Dynamics

<p>Deep-pocketed investors have adopted a bearish approach towards Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ADBE usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Adobe. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 13% leaning bullish and 60% bearish. Among these notable options, 8 are puts, totaling $3,892,070, and 7 are calls, amounting to $412,007.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $310.0 and $540.0 for Adobe, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Adobe options trades today is 560.69 with a total volume of 1,355.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Adobe's big money trades within a strike price range of $310.0 to $540.0 over the last 30 days.</p>
<h3>Adobe Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746547248_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$48.1</td>
<td>$46.05</td>
<td>$47.5</td>
<td>$400.00</td>
<td>$3.3M</td>
<td>2.2K</td>
<td align="right">701</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$17.15</td>
<td>$17.05</td>
<td>$17.15</td>
<td>$370.00</td>
<td>$171.4K</td>
<td>595</td>
<td align="right">146</td>
</tr>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$34.75</td>
<td>$33.6</td>
<td>$33.6</td>
<td>$510.00</td>
<td>$168.0K</td>
<td>103</td>
<td align="right">50</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/17/27</td>
<td>$143.3</td>
<td>$143.05</td>
<td>$143.3</td>
<td>$510.00</td>
<td>$114.6K</td>
<td>15</td>
<td align="right">9</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$22.85</td>
<td>$22.8</td>
<td>$22.85</td>
<td>$360.00</td>
<td>$89.1K</td>
<td>982</td>
<td align="right">39</td>
</tr>
</tbody>
</table>
</p>
<h3>About Adobe</h3>
<p>Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).</p>
<p>Having examined the options trading patterns of Adobe, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Adobe</h3>
<ul>
<li>Trading volume stands at 806,262, with ADBE's price up by 1.05%, positioned at $385.07.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 37 days.</li>
</ul>
<h3>Expert Opinions on Adobe</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $460.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from RBC Capital persists with their Outperform rating on Adobe, maintaining a target price of $480.<br />
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Adobe, maintaining a target price of $510.<br />
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Adobe with a target price of $380.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Adobe, which currently sits at a price target of $430.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Adobe, targeting a price of $500. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Adobe, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


ADBE

Adobe Options Trading: A Deep Dive into Market Sentiment

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Novo Nordisk</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NVO, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 22 uncommon options trades for Novo Nordisk.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 59% bullish and 36%, bearish.</p>
<p>Out of all of the special options we uncovered, 8 are puts, for a total amount of $290,690, and 14 are calls, for a total amount of $636,813.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $60.0 to $100.0 for Novo Nordisk over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Novo Nordisk stands at 1533.56, with a total volume reaching 11,513.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Novo Nordisk, situated within the strike price corridor from $60.0 to $100.0, throughout the last 30 days.</p>
<h3>Novo Nordisk 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746547242_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/09/25</td>
<td>$1.92</td>
<td>$1.82</td>
<td>$1.92</td>
<td>$69.00</td>
<td>$105.0K</td>
<td>1.7K</td>
<td align="right">944</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.05</td>
<td>$6.8</td>
<td>$6.85</td>
<td>$100.00</td>
<td>$68.3K</td>
<td>1.4K</td>
<td align="right">102</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.85</td>
<td>$12.5</td>
<td>$12.5</td>
<td>$65.00</td>
<td>$62.5K</td>
<td>2.1K</td>
<td align="right">87</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$10.3</td>
<td>$10.1</td>
<td>$10.3</td>
<td>$85.00</td>
<td>$51.5K</td>
<td>2.5K</td>
<td align="right">50</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/09/25</td>
<td>$1.03</td>
<td>$0.98</td>
<td>$1.03</td>
<td>$64.00</td>
<td>$49.4K</td>
<td>524</td>
<td align="right">20</td>
</tr>
</tbody>
</table>
</p>
<h3>About Novo Nordisk</h3>
<p>With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.</p>
<p>In light of the recent options history for Novo Nordisk, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Novo Nordisk's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 4,509,228, the NVO's price is down by -3.23%, now at $66.89. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 1 days.</li>
</ul>
<h3>Expert Opinions on Novo Nordisk</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $64.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from BMO Capital lowers its rating to Market Perform with a new price target of $64.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Novo Nordisk's Options: A Look at What the Big Money is Thinking

<p><strong>Arch Capital Group's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NYSE">ACGL</a>) short percent of float has fallen 6.67% since its last report. The company recently reported that it has <strong>4.98 million shares sold short</strong>, which is 1.54% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.53 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Arch Capital Group Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746547232_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Arch Capital Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Arch Capital Group's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Arch Capital Group's peer group average for short interest as a percentage of float is 2.38%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

ACGL

What's Driving the Market Sentiment Around Arch Capital Group?

Press Releases

Jowell Global Ltd. Announces First Half 2024 Unaudited Financial Results

JWEL

BARK

Big 5 Sporting Goods Corporation - Common Stock

Big 5 Sporting Goods

Boqii Holding Limited American Depositary Shares (each representing one hundred fifty (150) Class A Ordinary Shares)

Comments

Jowell Global

Interés en corto

Jowell Global (NASDAQ:JWEL) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL